Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8430832 | Biology of Blood and Marrow Transplantation | 2016 | 29 Pages |
Abstract
Hematopoietic stem cell transplantation (HSCT) has an integral role in the treatment of malignant and nonmalignant diseases. Long-term complications after HSCT have been well established and include graft-versus-host disease (GVHD), conditioning regimen-related toxicities, disease relapse, and infections. Immune-mediated phenomena are increasingly described after HSCT with clinically significant sequelae. Diagnosis is challenging because of features that overlap with other commonly reported post-transplantation complications. Patients who experience immune-mediated disease after HSCT tend to have poor outcomes. Early recognition of immune-mediated complications is imperative to reduce preventable morbidity and mortality. This review looks at the currently available literature on pathogenesis, incidence, risk factors, treatment, and outcomes of immune-mediated disease (other than GVHD) after HSCT.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Zhuoyan Li, Samuel M. Rubinstein, Ramya Thota, Malvi Savani, Eolia Brissot, Bronwen E. Shaw, Navneet S. Majhail, Mohamad Mohty, Bipin N. Savani,